REDEFINING DIAGNOSTICS

Revolutionizing the efficient use of NGS (Next-Generation Sequencing) in precision diagnostics

Redefining accessible

Genomill Health is a precision diagnostics company with a mission to disrupt the use of molecular diagnostic tests – liquid biopsies and beyond. We want to harness the use of the Next-Generation-Sequencing in diagnostics to the next level with our novel patented Geno1® sample preparation technology, enabling unprecedented improvements in performance and scalability.

Reduced cost

From 1500 USD to

1499

Increased accuracy

From 0,25% to

< 0.25 %

Faster turn-around-time

From 14 days to

14

Geno1

DRIVEN BY WORLD-CLASS RESEARCH

Our Geno1® technology is a unique combination of molecular biology, robotics, next-generation DNA sequencing and artificial intelligence.

It truly provides means for unprecedented scaling of liquid biopsies and beyond by tackling the main drivers: cost, accuracy, turn-around-time and scalability

Join our journey

We’re set to saturate the scattered liquid biopsy space with our technology. We offer Geno1® for out-licensing and are continuously looking for new long-term partnerships within oncology and other verticals – such as tropical and infectious diseases, NIPT, antibiotic resistance.

Join us in harnessing a true game-changing technology!

Latest news

<font color="#4B9CD2"> Genomeweb: </font> Genomill Health Positioning Geno1 Technology to Improve Liquid Biopsy Sequencing

Genomeweb: Genomill Health Positioning Geno1 Technology to Improve Liquid Biopsy Sequencing

 NEW YORK – After closing an investment round last month for an undisclosed sum, Finnish firm Genomill Health is aiming…
Genomill Health closes investment round to expand beta-testing with liquid biopsy players

Genomill Health closes investment round to expand beta-testing with liquid biopsy players

Genomill Health closes a financing round led by a deep tech VC Voima Ventures to expand its novel and disruptive…